

Application News

Liquid Chromatography Mass Spectrometry

Quantitation of Endogenous Steroids in Serum Using Dried Blood Spot Serum Separator Card and Triple Quadrupole Mass Spectrometry

No. LCMS-152


■ Introduction

Endogenous steroids are essential to the regulation of several metabolic pathways including energy metabolism, stress, and fertility. Dried blood spots (DBS) (**Figure 1**) offer an alternative to conventional venipuncture blood collection by allowing less invasive sample collection at home. A challenge for the lab is the small sample size collected from the dried blood spot resulting in low concentrations of endogenous analytes.

To assist with accurate quantitation of select steroids in this biological matrix, Dispersive Pipette XTRaction (DPX) technology was utilized for increased sensitivity and selectivity by reducing matrix interference. A Shimadzu LCMS-8060NX triple quadrupole mass spectrometry with its sensitive quantitation capability was used to analyze four endogenous steroids (**Figure 2**). Optimized source conditions and MRM transitions on the mass spectrometer were used to detect clinically relevant concentration limits in matrix. Correlation between traditional immunoassay assays and this newly developed LC-MS/MS method was determined using eight unique human serum samples.



Figure 1: Two types of DBS cards. Left card produces \sim 30 μ L of serum; right produces \sim 6 μ L serum.






Figure 2: Four steroids quantitated in this LC-MS/MS method.

Progesterone

■ Experimental

Testosterone

Materials and Sample Preparation

A six-point calibration curve with three QC levels were prepared from commercially available steroid standards (Cerilliant, TX) spiked in stripped human serum (Golden West, CA). Correlation samples were prepared by charging blank ADx cards with serum from venous drawn samples. The ADx sample cards were dried overnight and stored in the aluminum Ziploc sealed shipping bags provided with the cards.

Thirty microliter aliquots of each calibrator and QC were plated, while the ADx card samples were paper punched into culture tubes. All samples were spiked with internal standard and submerged in a water:methanol solution and incubated on a platerocker for 25min. The samples were then transferred to a well plate and the reconstituted protein was digested with 0.5% formic acid in 50% methanol in water prior to dSPE.

Each sample was exposed to DPX XTR tips containing 20mg SupelTM Swift HLB (60 μ m) (DPX170357) sorbent to isolate the target analytes from the matrix and further remove interferences using the Bind-Wash-Elute protocol as shown in **Figure 3**. DPX's patented technology provides dispersive SPE in a pipette tip that improves recovery by allowing the loose sorbent to mix more efficiently with the sample solution and increases the available surface area of the sorbent for more adequate sample binding than other traditional SPE products.

Bind - Wash - Elute



Figure 3: DPX Sample Preparation Procedure. Bind and wash solution: 50% methanol in water. Elution solution: acetonitrile.

Analytical Methods

Standards and samples were analyzed using the LCMS-8060NX triple quadrupole mass spectrometer coupled to Nexera HPLC equipped with a pump, autosampler, column oven as shown in **Figure 4**. Two column stationary phases (biphenyl and C18) were tested for evaluation. The biphenyl column was used for initial evaluation for correlation samples. The C18 column resulted in less matrix interferences with minimal gradient adjustments for spiked serum calibration and QC samples. The analytical conditions for both columns tested for this evaluation along with MS/MS conditions are listed in **Table 1**.



Figure 4: LCMS-8060NX configuration. The lonFocus design improves signal intensity with higher gas flows and higher effective temperatures. The probe position can be moved further from the MS inlet without losing signal intensity.

Table 1: HPLC and MS/MS Conditions

[LC Condition 1]		[LC Common Conditions]			
Column:	Shim-pack Velox C18 (100mm x 3.0mm I.D., 2.7µm	Mobile Phase A:	0.1mM ammonium fluoride in water		
Gradient Program:	B 50% (0-0.1min); B 95% (0.1-4min); B 95% (4.0-5min); B 50% (5.01-7min)	Mobile Phase B:	Methanol		
Flow Rate:	0.6mL/min	[MS/MS Condition	ıs]		
Column Temperature:	40 ℃	Ionization:	ESI (+) and (-) mode		
Injection Volume:	10μL	Mode:	MRM		
[LC Condition 2]		Interface Voltage:	+3.0 kV/-3.0 kV		
Column:	Shim-pack Velox Biphenyl (100mm x 3.0mm I.D., 3.0 μm	Focus Voltage	2kV		
Gradient Program:	B 30% (0min); B 55% (0.0-1min); B 80% (1.0-4.5min); B 80% (4.5min-6.3min); B 98% (6.30-6.31min); B 98% (6.31min-7.31min); B 30% (7.32min-8.7min)	Nebulizing gas flow:	3 L/min		
Flow Rate:	0.8mL/min	Drying gas flow:	15 L/min		
Column Temperature:	50 °C	Heating gas flow:	25 L/min		
Injection Volume:	20uL	DL Temp:	250 °C		
		Heat Block Temp:	500 °C		

MRM Transitions

The quantitative and qualitative MRM transitions used for analysis are shown in **Table 2**.

Table 2: MRM transitions

Analyte	Ret. Time, (min), biphenyl	Ret. Time, (min), C18	Quant. Transition	Collision Energy (V)	Qual. Transition	Collision Energy (V)	Polarity
DHEAS-d5	2.023*	2.323*	372.10>98.0	13.0			-
DHEAS	2.029*	2.401*	367.05>97.05	13.0			-
Cortisol-d5	3.021	2.136	367.20>121.10	-23.0			+
Cortisol	3.034	2.142	363.20>105.10	-21.0	363.20	-23.0	+
Testosterone-d3	4.824	3.120	292.20>109.10	-23.0			+
Testosterone	4.834	3.125	289.20>109.10	-23.0	289.20>97.10	-22.0	+
Progesterone-d9	6.608	3.787	324.30>113.15	-11.0			+
Progesterone	6.690	3.812	315.20>109.05	-11.0	315.20>97.10	-17.0	+

^{*}adequate column conditioning should be completed to avoid retention time shifting for DHEAS

■ Results

Calibrators and QCs

Representative calibration curves and chromatograms for calibrator 1 using 30µL serum aliquots for biphenyl and C18 column phases are show in **Figure 5** and **Figure 6**. Correlation of coefficient (r²) values were above 0.99 for all analytes and percent accuracy was between 80-120% for all calibration and QC levels.

Intra-day (n=6) and Inter-day (n=21, 4 days) for replicate QC injection were less than 8% RSD as shown in **Table 3**.




Figure 5: Calibration curves and chromatogram for calibrator 1 on C18 column.




Figure 6: Calibration curves and chromatogram for calibrator 1 on biphenyl column.

Table 3: Intra- and inter-day precision for each QC level on C18 column.

Analyte	Sample ID	Intra-day %RSD (n=6)	Inter-day %RSD (n=21, 4 days)		
	LowQC	2.46	2.26		
Cortisol	MidQC	1.15	1.31		
	HighQC	3.04	2.49		
	LowQC	2.52	2.3		
DHEAS	MidQC	2.64	2.38		
	HighQC	3.4	3.85		
	LowQC	4.84	5.39		
Testosterone	MidQC	1.81	1.94		
	HighQC	3.65	2.97		
	LowQC	5.46	7.2		
Progesterone	MidQC	2.98	2.22		
	HighQC	2.61	3.28		

Correlation

Correlation comparing immunoassay results for eight human venous drawn samples to this newly developed quantitative method is shown in **Table 4**. Each sample was charged with 30µL of serum on ADx cards. The percent difference for all analytes compared to immunoassay results were less than 30% for all analytes in all samples. A representative sample chromatogram is shown in **Figure 7**.

Table 4: Correlation comparing LCMS results from charged ADx DBS cards vs. immunoassay

	DHEAs		Cortsol			Testosterone			Progesterone			
Sample	Conc.	Conc. (ng/mL)		Conc. (ng/mL)			Conc. (ng/mL)			Conc. (ng/mL)		
Name LCMS	Immunoassay	%Diff	LCMS	Immunoassay	%Diff	LCMS	Immunoassay	%Diff	LCMS	Immunoassay	%Diff	
Sample A	779	763	-2.0	66	66	0.1	0.13	0.15	14.9	4.32	5.29	18.3
Sample B	4133	4099	-0.8	115	126	8.8	0.24	0.32	26.5	3.72	3.89	4.4
Sample C	1257	1234	-1.9	87	102	14.5	10.63	15	29.1	0.35	0.43	18.3
Sample D	2057	1825	-12.7	102	105	3.1	1.65	2	17.3	0.36	0.36	1.5
Sample E	3109	2585	-20.3	89	92	3.3	1.8	2	9.9	0.37	0.32	-14.2
Sample F	3769	3373	-11.7	202	241	16.2	1.47	1.66	11.3	0.37	0.34	-10.6
Sample G	526	513	-2.5	147	150	2.1	0.11	0.15	24.1	0.63	0.55	-14.2
Sample H	767	909	15.7	63	70	10.0	0.1	0.13	20.0	0.69	0.77	9.7




Figure 7: Chromatogram for Sample B on biphenyl column

■ Conclusion

A highly sensitive and accurate LC-MS/MS method was developed for the quantification of four steroids on ADx DBS cards, with calibration ranges for all compounds within published reference ranges. The sensitivity of LC-MS/MS analysis using the small sample volume from DBS has been comparable to classical immunoassay for all analytes.

This method has shown that fingerstick collection on DBS cards could potentially be a substitute to conventional venipuncture blood collection.

















LCMS-8040

LCMS-8045

LCMS-8050

LCMS-8060NX

LCMS-2020 LCMS-2050 Q-TOF LCMS-9030/9050

Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation built on the foundation of contributing to society through science and technology. Established in 1975, Shimadzu Scientific Instruments (SSI), the American subsidiary of Shimadzu Corporation, provides a comprehensive range of analytical solutions to laboratories throughout North, Central, and parts of South America. SSI maintains a network of ten regional offices strategically located across the United States, with experienced technical specialists, service and sales engineers situated throughout the country, as well as applications laboratories on both coasts.

For information about Shimadzu Scientific Instruments and to contact your local office, please visit our Web site at www.ssi.shimadzu.com



Shimadzu Corporation www.shimadzu.com/an/

SHIMADZU SCIENTIFIC INSTRUMENTS, INC. Applications Laboratory 7102 Riverwood Drive, Columbia, MD 21045 Phone: 800-477-1227 Fax: 410-381-1222 www.ssi.shimadzu.com

For Research Use Only. Not for use in diagnostic procedures. The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to is accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice

First Edition: September 2023